查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1873982

過敏免疫療法市場

Allergy Immunotherapies Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024年，過敏免疫療法市值約為27.9億美元，預計到2031年將成長至51.1億美元，2031年之前的年複合成長率（CAGR）為9.0%。預計將影響過敏免疫療法市場的關鍵趨勢包括創新給藥方法的開發、聯合療法的興起以及個人化醫療的進步。

過敏免疫療法市場分析

全球過敏性疾病發生率的不斷上升有望推動過敏免疫療法市場的成長。過敏性疾病數量的增加迫切需要有效的治療方法，例如過敏免疫療法。過敏免疫療法被公認為一種安全有效的治療方法，可用於控制昆蟲黴菌、花粉、動物皮屑等過敏原以及過敏性氣喘。根據美國過敏、氣喘和免疫學會統計，2021年，美國有三分之一的成年人和超過四分之一的兒童報告患有季節性過敏、濕疹或食物過敏。

全球範圍內過敏症的日益普遍推動了對免疫療法的需求，從而促進了市場擴張。

過敏免疫療法市場概覽

全球過敏免疫療法市場按地區分類為北美、歐洲、亞太、中東和非洲以及南美和中美洲。預計該市場將因過敏性疾病盛行率上升和舌下給藥製劑技術進步等因素而成長。然而，過敏免疫療法應用方面的挑戰以及各地區監管差異可能會在預測期內阻礙市場成長。

戰略洞察

過敏免疫療法市場的促進因素與機遇

人們對過敏治療的認知提高預計將有利於市場發展。

大眾對過敏及其治療方案的認知不斷提高，推動了對更有效療法的需求。人們希望緩解那些嚴重影響生活品質的症狀。

州教育總監辦公室 (OSSE) 和衛生與保健部門將 2023 年 5 月 14 日至 20 日定為食物過敏意識週，重點是向公眾普及食物過敏和過敏性休克的相關知識。

強大的產品線為過敏免疫療法市場帶來了機會

目前，過敏性免疫療法研發管線包含 15 種處於不同臨床開發階段的療法。參與過敏性疾病免疫療法研發的主要企業包括 Aimmune Therapeutics Inc.、DBV Technologies SA、Genentech Inc.、ASIT biotech SA、Inmunotek SL、Anergis SA、Biomay AG 和 Regeneron Pharmaceuticals Inc.。

臨床試驗中多種免疫療法的積極臨床結果支持了過敏免疫療法藥物的研發進展。例如，2022年11月，FDA授予Alladapt Immunotherapeutics公司的ADP101快速通道資格，ADP101是一種針對重要食物過敏原的在研口服免疫療法。

對過敏免疫療法市場進行分析的關鍵細分市場包括服務和應用。

  • 按治療類型分類，過敏免疫療法市場分為皮下免疫療法 (SCIT) 和舌下免疫療法 (SLIT)。 2023 年，SCIT 佔據最大的市場佔有率，而預計在預測期內，SLIT 市場將實現最快的成長。
  • 依過敏類型分類，市場可分為過敏性鼻炎、氣喘、食物過敏、毒液過敏和其他過敏。 2023年，過敏性鼻炎市佔率最大，預計在預測期內將維持最高的複合年成長率。
  • 過敏免疫療法市場按配銷通路可細分為醫院藥房、零售藥房和線上藥房。 2023年，醫院藥局管道佔據最大的市場佔有率，預計在預測期內也將保持最快的成長速度。

過敏免疫療法的地理市場佔有率分析

過敏免疫療法市場報告的地理範圍分為五個地區：北美、亞太地區、歐洲、中東和非洲以及南美/中南美洲。

北美地區（包括美國、加拿大和墨西哥）佔據過敏免疫療法市場最大的佔有率，其中美國市場佔有率領先，加拿大緊隨其後。美國市場佔有率顯著成長主要歸因於過敏性疾病盛行率的不斷上升，這推動了對過敏免疫療法的需求，進而促進了市場成長。此外，許多專注於過敏免疫療法的製造商也促進了美國市場的擴張。同時，消費者對過敏治療的認知不斷提高，也增加了北美地區對醫用氧氣的需求。

亞太地區預計將成為所有區域中成長最快的地區。由於澳洲和印度等國家過敏和免疫性疾病的高發，亞太市場預計將快速成長。此外，各國政府旨在預防和治療疾病的措施預計將為該地區創造有利的市場成長環境。同時，醫療基礎設施的改善和研發投入的增加預計也將推動亞太地區過敏免疫療法市場在預測期內的成長。

過敏免疫療法市場報告範圍

過敏免疫療法市場最新動態及新聞

過敏免疫療法市場評估是基於從一手和二手研究中收集的定性和定量資料，包括重要的企業出版物、協會資料和資料庫。以下是過敏免疫療法市場的一些最新發展和策略：

  • 2020年8月，雀巢健康科學收購了Aimmune Therapeutics公司。 Aimmune公司已獲批准的療法Palforzia是第一個也是目前唯一一個獲得FDA批准的、用於降低兒童花生過敏反應頻率和嚴重程度的藥物，這將豐富雀巢健康科學的產品組合。 （來源：公司新聞稿）
  • 2023年9月，Stallergenes Greer與雀巢健康科學公司達成協議，使用花生過敏口服免疫療法藥物Palforzia。 （來源：公司新聞稿）

過敏免疫療法市場報告的覆蓋範圍和交付成果

這份題為《過敏免疫療法市場規模及預測（2021-2031）》的報告對市場進行了全面分析，涵蓋以下領域：

  • 涵蓋範圍內所有關鍵細分市場的全球、區域和國家層面的市場規模和預測
  • 市場動態，例如促進因素、限制因素和關鍵機會
  • 未來主要趨勢
  • 詳細的PEST/波特五力模型與SWOT分析
  • 全球及區域市場分析，涵蓋關鍵市場趨勢、主要參與者、法規及近期市場發展動態。
  • 產業格局和競爭分析，包括市場集中度、熱力圖分析、主要參與者和最新發展動態
  • 公司詳細概況

目錄

第1章：引言

第2章：過敏免疫療法市場及主要結論

第3章：研究方法

  • 覆蓋範圍
  • 二手研究
  • 初步研究

第4章：過敏免疫療法市場及市場概況

  • 概述
  • PEST分析
    • 北美和PEST分析
    • 歐洲和PEST分析
    • 亞太地區及PEST分析
    • 中東和非洲 (MEA) 及 PEST 分析
    • 南美洲和中美洲以及 PEST 分析
  • 專家意見

第5章：過敏免疫療法市場及主要市場動態

  • 主要市場促進因素
    • 過敏性疾病盛行率不斷上升
    • 舌下給藥製劑的技術進步
  • 關鍵市場限制因素
    • 使用過敏免疫療法的缺點
    • 不同地區監理差異
  • 主要市場機遇
    • 強大的產品線
  • 未來趨勢
    • 增加FDA對藥物的批准
  • 影響分析

第6章：過敏免疫療法市場及全球分析

  • 全球過敏免疫療法市場收入預測與分析
  • 全球過敏免疫療法市場（按地域分類）－預測與分析
  • 關鍵參與者的市場定位

第7章：過敏免疫療法市場分析及治療方法

  • 概述
  • 按治療方法分類的過敏免疫療法市場佔有率，2024 年和 2031 年（%）
  • 皮下免疫療法（SCIT）
  • 舌下免疫療法（SLIT）

第8章：過敏免疫療法市場分析及依過敏類型分類

  • 概述
  • 按過敏類型分類的過敏免疫療法市場佔有率，2024 年和 2031 年（%）
  • 過敏性鼻炎
  • 氣喘
  • 食物過敏
  • 毒液過敏
  • 其他過敏

第9章：過敏免疫療法市場分析及配銷通路

  • 概述
  • 按配銷通路分類的過敏免疫療法市場佔有率，2024 年和 2031 年（%）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章：過敏免疫療法市場分析及至2031年預測及地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
  • 南美洲和中美洲
    • 巴西
    • 阿根廷

第11章：新冠肺炎疫情對全球過敏免疫療法市場的影響

  • 北美洲
  • 歐洲
  • 亞太地區
  • 世界其他地區

第12章：過敏免疫療法市場及產業概況

  • 概述
  • 市場中各公司採取的成長策略（%）
  • 有機發展
    • 概述
  • 無機物發展
    • 概述

第13章：公司簡介

  • ALK-Abello A/S
  • AIMMUNE THERAPEUTICS, INC.
  • LETIPharma
  • Stallergenes Greer
  • HAL Allergy B.V.
  • Johnson and Johnson Services, Inc.
  • Anergis
  • DBV Technologies
  • Dermapharm Holding
  • Allergy Therapeutics

第14章：附錄

簡介目錄
Product Code: TIPRE00008219

The allergy immunotherapies market was valued at approximately US$ 2.79 billion in 2024 and is anticipated to grow to US$ 5.11 billion by 2031, with a compound annual growth rate (CAGR) of 9.0% through 2031. Key trends expected to shape the allergy immunotherapies market include the development of innovative delivery methods, the rise of combination therapies, and advancements in personalized medicine.

Analysis of the Allergy Immunotherapies Market

The increasing incidence of allergic disorders globally is likely to propel the growth of the allergy immunotherapies market. The rising number of allergic conditions necessitates effective treatments such as allergy immunotherapy, which is recognized as a safe and effective approach to managing allergens like insect molds, pollen, and animal dander, as well as allergic asthma. According to the American College of Allergy, Asthma & Immunology, in 2021, one in three adults and over one in four children in the United States reported experiencing seasonal allergies, eczema, or food allergies.

The escalating prevalence of allergies worldwide is driving the demand for immunotherapies, thereby supporting market expansion.

Overview of the Allergy Immunotherapies Market

The global allergy immunotherapies market is categorized by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Growth in this market is anticipated due to factors such as the rising prevalence of allergic disorders and technological advancements in sublingual dosage forms. However, challenges related to the use of allergy immunotherapies and regulatory differences across regions may hinder market growth during the forecast period.

Strategic Insights

Drivers and Opportunities in the Allergy Immunotherapies Market

Increased Awareness of Allergy Treatments is Expected to Benefit the Market

Growing public awareness regarding allergies and their treatment options is driving the demand for improved therapies. Individuals are seeking relief from symptoms that can significantly affect their quality of life.

The Office of the State Superintendent of Education (OSSE) and the Division of Health & Wellness recognized Food Allergy Awareness Week from May 14 to May 20, 2023, focusing on educating the public about food allergies and anaphylaxis.

Strong Product Pipeline Represents an Opportunity in the Allergy Immunotherapies Market

The pipeline for allergy immunotherapy includes 15 therapies at various clinical development stages. Key players involved in developing immunotherapies for allergic conditions include Aimmune Therapeutics Inc., DBV Technologies S.A., Genentech Inc., ASIT biotech SA, Inmunotek SL, Anergis S.A., Biomay AG, and Regeneron Pharmaceuticals Inc.

Positive clinical outcomes from various immunotherapies in clinical trials support the advancement of allergy immunotherapy drugs. For example, in November 2022, the FDA granted Fast Track designation to Alladapt Immunotherapeutics' ADP101, an investigational oral immunotherapy targeting significant food allergens.

Key segments contributing to the analysis of the allergy immunotherapies market include services and applications.

  • By treatment type, the allergy immunotherapies market is divided into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In 2023, the SCIT segment accounted for the largest market share, while the SLIT segment is projected to experience the fastest growth during the forecast period.
  • By allergy type, the market is segmented into allergic rhinitis, asthma, food allergies, venom allergies, and others. The allergic rhinitis segment held the largest market share in 2023 and is expected to register the highest CAGR during the forecast period.
  • The allergy immunotherapies market is also segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. In 2023, the hospital pharmacy segment held the largest market share and is anticipated to grow the fastest during the forecast period.

Geographical Market Share Analysis of Allergy Immunotherapies

The geographical scope of the allergy immunotherapies market report is divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South America/South & Central America.

North America, which includes the US, Canada, and Mexico, holds the largest share of the allergy immunotherapies market, with the US leading in market share, followed by Canada. The significant market share in the US is attributed to the increasing prevalence of allergic disorders, which boosts the demand for allergy immunotherapy and drives market growth. Additionally, the presence of numerous manufacturers specializing in allergy immunotherapy contributes to market expansion in the country. Furthermore, rising consumer awareness regarding allergy treatments has increased the demand for health supplemental oxygen in North America.

The Asia Pacific region is expected to be the fastest-growing area among all regions. The market in Asia Pacific is projected to grow rapidly due to the high prevalence of allergic and immunological diseases in countries like Australia and India. Moreover, government initiatives aimed at prevention and treatment strategies are expected to create a favorable market growth environment in the region. Additionally, improvements in healthcare infrastructure and increased investments in research activities are anticipated to drive the growth of the Asia Pacific Allergy Immunotherapies Market during the forecast period.

Scope of the Allergy Immunotherapies Market Report

Recent Developments and News in the Allergy Immunotherapies Market

The allergy immunotherapies market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the allergy immunotherapies market:

  • In August 2020, Nestle Health Science acquired Aimmune Therapeutics. Aimmune's approved therapy, Palforzia, would enhance Nestle Health Science's portfolio as the first and only FDA-approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children. (Source: Company Press Release)
  • In September 2023, Stallergenes Greer entered into an agreement with Nestle Health Science to utilize the peanut allergy oral immunotherapy treatment, Palforzia. (Source: Company Press Release)

Coverage and Deliverables of the Allergy Immunotherapies Market Report

The report titled "Allergy Immunotherapies Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
  • Detailed company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Allergy Immunotherapies Market and By Treatment
    • 1.3.2 Allergy Immunotherapies Market and By Allergy Type
    • 1.3.3 Allergy Immunotherapies Market and By Distribution Channel
    • 1.3.4 Allergy Immunotherapies Market and By Geography

2. Allergy Immunotherapies Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Allergy Immunotherapies Market and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America and PEST Analysis
    • 4.2.2 Europe and PEST Analysis
    • 4.2.3 Asia-Pacific and PEST Analysis
    • 4.2.4 Middle East and Africa (MEA) and PEST Analysis
    • 4.2.5 South and Central America and PEST Analysis
  • 4.3 Expert Opinion

5. Allergy immunotherapies Market and Key Market Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Growing Prevalence of Allergic Disorders
    • 5.1.2 Technological Advancements in Sublingual Dosage Formulations
  • 5.2 Key Market Restraint
    • 5.2.1 Drawbacks Associated with the Use of Allergy Immunotherapy
    • 5.2.2 Regulatory Variations Across Regions
  • 5.3 Key Market Opportunities
    • 5.3.1 Presence of Strong Product Pipeline
  • 5.4 Future Trends
    • 5.4.1 Increasing FDA Approvals for Drugs
  • 5.5 Impact Analysis

6. Allergy Immunotherapies Market and Global Analysis

  • 6.1 Global Allergy Immunotherapies Market Revenue Forecast And Analysis
  • 6.2 Global Allergy immunotherapies market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Allergy Immunotherapies Market Analysisand by Treatment

  • 7.1 Overview
  • 7.2 Allergy Immunotherapies Market Share, By Treatment, 2024 and 2031 (%)
  • 7.3 Subcutaneous Immunotherapy (SCIT)
    • 7.3.1 Overview
    • 7.3.2 Subcutaneous Immunotherapy (SCIT) Market Revenue and Forecasts to 2031 (US$ Million)
  • 7.4 Sublingual Immunotherapy (SLIT)
    • 7.4.1 Overview
    • 7.4.2 Sublingual Immunotherapy (SLIT) Market Revenue and Forecasts to 2031 (US$ Million)

8. Allergy Immunotherapies Market Analysisand by Allergy Type

  • 8.1 Overview
  • 8.2 Allergy Immunotherapies Market Share, By Allergy Type, 2024 and 2031 (%)
  • 8.3 Allergic Rhinitis
    • 8.3.1 Overview
    • 8.3.2 Allergic Rhinitis Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.4 Asthma
    • 8.4.1 Overview
    • 8.4.2 Asthma Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.5 Food Allergy
    • 8.5.1 Overview
    • 8.5.2 Food Allergy Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.6 Venom Allergy
    • 8.6.1 Overview
    • 8.6.2 Venom Allergy Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.7 Other Allergies
    • 8.7.1 Overview
    • 8.7.2 Others Market Revenue and Forecasts to 2031 (US$ Million)

9. Allergy Immunotherapies Market Analysisand by Distribution Channel

  • 9.1 Overview
  • 9.2 Allergy Immunotherapies Market Share, By Distribution Channel, 2024 and 2031 (%)
  • 9.3 Hospital Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacy Market Revenue and Forecasts to 2031 (US$ Million)
  • 9.4 Retail Pharmacy
    • 9.4.1 Overview
    • 9.4.2 Retail Pharmacy Market Revenue and Forecasts to 2031 (US$ Million)
  • 9.5 Online Pharmacy
    • 9.5.1 Overview
    • 9.5.2 Online Pharmacy Market Revenue and Forecasts to 2031 (US$ Million)

10. Allergy Immunotherapies Market Analysis And Forecasts To 2031 and Geographical Analysis

  • 10.1 North America: Allergy immunotherapies market
    • 10.1.1 Overview
    • 10.1.2 North America : Allergy immunotherapies market - Revenue and Forecast to 2031 (US$ Million)
    • 10.1.3 North America: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.1.4 North America Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.1.5 North America Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.6 North America: Allergy immunotherapies market, by Country, 2024 and 2031 (%)
    • 10.1.7 US: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.1 US: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.2 US Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.3 US Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.4 US Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.8 Canada: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.1 Canada: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.2 Canada Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.3 Canada Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.4 Canada Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.9 Mexico: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.1 Mexico: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.2 Mexico Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.3 Mexico Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.4 Mexico Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.1 Europe: Allergy Immunotherapies Market
    • 10.1.1 Overview
    • 10.1.2 Europe: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
    • 10.1.3 Europe: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.1.4 Europe: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.1.5 Europe: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.6 Europe: Allergy Immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.1.7 Germany: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.1 Germany: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.2 Germany: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.3 Germany: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.4 Germany: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.8 France: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.1 France: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.2 France: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.3 France: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.4 France: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.9 UK: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.1 UK: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.2 UK: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.3 UK: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.4 UK: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.10 Italy: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.1 Italy: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.2 Italy: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.3 Italy: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.4 Italy: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.11 Spain: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.1 Spain: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.2 Spain: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.3 Spain: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.4 Spain: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.2 Asia-Pacific: Allergy Immunotherapies Market
    • 10.2.1 Overview
    • 10.2.2 Asia-Pacific: Allergy Immunotherapies Market - Revenue and Forecast to 2031 (USD Million)
    • 10.2.3 Asia-Pacific Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.2.4 Asia-Pacific Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.2.5 Asia-Pacific Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.6 Asia-Pacific: Allergy Immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.2.7 China: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.1 China: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Millkion)
      • 10.2.7.2 China Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.3 China Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.4 China Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.8 Japan: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.1 Japan: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.2 Japan Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.3 Japan Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.4 Japan Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.9 India: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.1 India: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.2 India Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.3 India Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.4 India Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.10 South Korea: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.1 South Korea: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.2 South Korea Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.3 South Korea Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.4 South Korea Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.11 Australia: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.1 Australia: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.2 Australia Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.3 Australia Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.4 Australia Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.3 Middle East and Africa: Allergy immunotherapies market
    • 10.3.1 Overview
    • 10.3.2 Middle East and Africa: Allergy immunotherapies market - Revenue and Forecast to 2031 (US$ Million)
    • 10.3.3 Middle East and Africa Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.3.4 Middle East and Africa Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.3.5 Middle East and Africa Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.3.6 Middle East and Africa: Allergy Immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.3.7 Saudi Arabia: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.1 Saudi Arabia: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.2 Saudi Arabia Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.3 Saudi Arabia Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.4 Saudi Arabia Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.3.8 UAE: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.1 UAE: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.2 UAE Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.3 UAE Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.4 UAE Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.3.9 South Africa: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.1 South Africa: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.2 South Africa Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.3 South Africa Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.4 South Africa Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.4 South and Central America: Allergy immunotherapies market
    • 10.4.1 Overview
    • 10.4.2 South and Central America: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
    • 10.4.3 South and Central America Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.4.4 South and Central America Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.4.5 South and Central America Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.4.6 South and Central America: Allergy immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.4.7 Brazil: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.1 Brazil: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.2 Brazil Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.3 Brazil Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.4 Brazil Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.4.8 Argentina: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.1 Argentina: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.2 Argentina Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.3 Argentina Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.4 Argentina Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)

11. Impact of COVID-19 Pandemic on Global Allergy Immunotherapies Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Allergy Immunotherapies Market and Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market, (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 ALK-Abello A/S
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AIMMUNE THERAPEUTICS, INC.
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 LETIPharma
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Stallergenes Greer
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 HAL Allergy B.V.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Johnson and Johnson Services, Inc.
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Anergis
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 DBV Technologies
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Dermapharm Holding
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Allergy Therapeutics
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 Glossary of Terms